A new prenatal test could reduce the expense of caring for those with Down’s Syndrome, says the UK Royal College of Obstetricians and Gynaecologists (RCOG).
In a recent submission to the National Screening Committee, the RCOG said that a “rigorous economic analysis” is needed to evaluate the benefits of rolling out Non-Invasive Prenatal Testing (NIPT).
If the decision has been made primarily on cost grounds, then a more rigorous economic analysis has to be made that includes the lifetime costs of caring for children and adults with Down’s syndrome (bearing in mind that cfDNA testing as a primary screen test will identify approximately 289 more babies with trisomies). Such an economic analysis may (or may not) suggest that cfDNA testing for all is cost-effective.
The RCOG submission was part of an NSC review into the impact of introducing NIPT.
Disability advocates have condemned RCOG’s suggestion, saying that it “puts a price on the life” of individuals with Down’s Syndrome.
‘It is utterly shocking that in this day and age someone can put a cost value on someone’s life just because they have a disability,” Dr. Elizabeth Corcoran of the Down’s Syndrome Research Foundation told The Daily Mail. “It is worse still that this comes from a respected Royal College that is a professional beacon for doctors.”
This article is published by
and BioEdge under a Creative Commons licence. You may republish it or translate it free of charge with attribution for non-commercial purposes following these guidelines
. If you teach at a university we ask that your department make a donation. Commercial media must contact us
for permission and fees. Some articles on this site are published under different terms.